Mark D. Tyson, II, MD, MPH

Articles by Mark D. Tyson, II, MD, MPH

Experts discuss how checkpoint inhibitors, cystectomy, and other treatment modalities fit into the current landscape for non–muscle-invasive bladder cancer.

Optimizing Therapeutic Strategies Across the NMIBC Paradigm

ByManojkumar Bupathi, MD, MS,Benjamin Garmezy, MD,Suzanne B. Merrill, MD, FACS,Mark D. Tyson, II, MD, MPH

May 14th 2026

Experts discuss how checkpoint inhibitors, cystectomy, and other treatment modalities fit into the current landscape for non–muscle-invasive bladder cancer.

Cretostimogene grenadenorepvec’s efficacy compares favorably with the current nonsurgical standards of care in high-risk, Bacillus Calmette Guerin–unresponsive non-muscle invasive bladder cancer.

Cretostimogene Grenadenorepvec May be ‘Attractive’ Option for NMIBC

ByMark D. Tyson, II, MD, MPH

December 1st 2023

Cretostimogene grenadenorepvec’s efficacy compares favorably with the current nonsurgical standards of care in high-risk, Bacillus Calmette Guerin–unresponsive non-muscle invasive bladder cancer.

Latest Updated Articles

Optimizing Therapeutic Strategies Across the NMIBC Paradigm
May 14th 2026

Trending on CancerNetwork

AI and MRD Take Center Stage on Day 2 of ASCO Breakthrough 2026

Pirtobrutinib Earns Positive CHMP Opinion Across All CLL Treatment Lines

40 An AI Digital Twin Compares Favorably to Radiologists for Landmark Identification and Measurement in Early-Stage Breast Cancer: A Retrospective, Multi-Institution Clinical Study

GLP-1 Receptor Agonists Reduce Colorectal Cancer Risk in IBD Populations

42 Intraoperative Frozen Analysis of Sentinel Lymph Nodes After Neoadjuvant Chemotherapy Does Not Provide Additional Surgical Benefit and Increases the Rate of Unnecessary ALND in Clinically Node-Negative Breast Cancer Patients